Skip to content

New Human Ocular Durability Data

New ABCD Formulation

New Pivotal Trial Designs

Learn more at our
Investor R&D Day

Our Company
Our Science
- ABCD Platform
- Scientific Presentations
Focus Areas
Our Pipeline
Our Culture
- Join the Team
Investors & Media

Our Company
Our Science
- ABCD Platform
- Scientific Presentations
Focus Areas
Our Pipeline
Our Culture
- Join the Team
Investors & Media

Tarcocimab Tedromer (KSI-301) 5 mg for the Treatment of RVO: One-Year Primary Efficacy, Durability, and Safety Outcomes of the Phase 3 BEACON Study

July 1, 2024

By

×

FORWARD LOOKING STATEMENTS

This site contains forward-looking statements and information. The use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Actual results could differ materially from those projected in such forward-looking statements.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

KODIAK SCIENCES GMBH
DAMMSTRASSE 19
6300 ZUG
SWITZERLAND

KODIAK SCIENCES VALAIS GMBH
ROTTENSTRASSE 5
3930 VISP
SWITZERLAND

FORWARD LOOKING STATEMENTS

FOLLOW
US

info@kodiak.com
COPYRIGHT © 2025 KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America